OncoMatch/Clinical Trials/NCT06035497
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Is NCT06035497 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies BMS-986369 for relapsed or refractory t-cell lymphomas.
Treatment: BMS-986369 — The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage IIB, III, IIIA, IIIB, IV, IVA, IVB
Mycosis fungoides (MF) with advanced stage (stage IIB-IVB)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Min 1 prior line
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify